Table 3.
Odds ratios a for prior use of any angiotensin-converting enzyme inhibitors (ACEIs) in individuals with villous atrophy as compared with general population matched controls.
| Villous atrophy (%) | Controls (%) | Odds ratio | 95% CI | P value | |
|---|---|---|---|---|---|
| Any ACEI b | 165/2933 (5.6) | 762/14,571 (5.2) | 1.08 | 0.90-1.30 | .41 |
| Sex | |||||
| Males | 99/1137 (8.7) | 418/5645 (7.4) | 1.22 | 0.95-1.56 | .12 |
| Females | 66/1796 (3.7) | 344/8926 (3.9) | 0.94 | 0.71-1.25 | .66 |
| Repeated prescriptions of any ACEI | 160/2928 (5.5) | 751/14,560 (5.2) | 1.06 | 0.88-1.28 | .52 |
| Use of ACEI > 1 year before biopsy | 47/2815 (1.7) | 238/14,047 (1.7) | 1.01 | 0.72-1.41 | .98 |
ACEIs, angiotensin-converting enzyme inhibitors; CI, confidence interval.
a
Odds ratios estimated through conditional logistic regression. Through this statistical approach all analyses were carried out stratumwise and thereby conditioned on age at time of biopsy (and corresponding date in controls), calendar period, sex and county of residence.
b
Any ACEI (ATC-code: C09) used between July 1st 2005 and January 29th 2008.